abstract |
The invention relates to a sustained-release formulation for oral administration, comprising a substance chosen from pindolol and an ester of 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydroxy-2,6-dimethyl- 3,5-pyridinedicarboxylic acid, a pharmaceutically acceptable hydrophilic swelling substance and optionally a pharmaceutically acceptable inert fat. |